Cancer

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)…

11 months ago

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)…

11 months ago

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

11 months ago

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new…

11 months ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…

11 months ago

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

11 months ago

Invitation to Presentation of Cantargia’s Year-End Report 2023 on February 22 at 3.00 p.m. CET

LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Cantargia (STO:CANTA) Cantargia AB will publish the company's year-end report for…

11 months ago

Invitation to Presentation of Cantargia’s Year-End Report 2023 on February 22 at 3.00 p.m. CET

LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Cantargia (STO:CANTA) Cantargia AB will publish the company's year-end report for…

11 months ago

Spago Nanomedical Year-end Report January-December, 2023

LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad®OCTOBER -…

11 months ago